BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30347389)

  • 1. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
    Li X; Gu G; Soliman F; Sanders AJ; Wang X; Liu C
    Chemotherapy; 2018; 63(4):214-219. PubMed ID: 30347389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
    Li N; Jin ZL; Liu ZJ; Wang J; Li K
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
    Wang B; Xu L; Li Q; Man S; Jin C; Liu L; Zhan S; Ning Y
    BMC Cancer; 2020 Oct; 20(1):1021. PubMed ID: 33087103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
    Han B; Xiu Q; Wang H; Shen J; Gu A; Luo Y; Bai C; Guo S; Liu W; Zhuang Z; Zhang Y; Zhao Y; Jiang L; Zhou J; Jin X
    J Thorac Oncol; 2011 Jun; 6(6):1104-9. PubMed ID: 21532504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
    Han BH; Xiu QY; Wang HM; Shen J; Gu AQ; Luo Y; Bai CX; Guo SL; Liu WC; Zhuang ZX; Zhang Y; Zhao YZ; Jiang LY; Shi CL; Jin B; Zhou JY; Jin XQ
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
    Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
    Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical Observation of Recombinant Human Vascular Endostatin Durative Transfusion Combined with Window Period Arterial Infusion Chemotherapy in the Treatment of 
Advanced Lung Squamous Carcinoma].
    Lv Y; Jiang R; Ma C; Li J; Wang B; Sun L; Mu N
    Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):500-4. PubMed ID: 26302347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first-line chemotherapy in patients with advanced non-small cell lung cancer.
    Cheng Y; Nie L; Liu Y; Jin Z; Wang X; Hu Z
    Thorac Cancer; 2019 Jul; 10(7):1576-1580. PubMed ID: 31161695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland.
    Zhu Q; Zang Q; Jiang ZM; Wang W; Cao M; Su GZ; Zhen TC; Zhang XT; Sun NB; Zhao C
    Asian Pac J Cancer Prev; 2015; 16(9):4013-8. PubMed ID: 25987078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer].
    Wang J; Li K; Sun T; Zhang MJ; Li WL; Yao Q; Liu W; Ding CM; He ZY; Mao WD; Wang HM; Zhang Y; Zhou XL
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):618-22. PubMed ID: 24314222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
    J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis.
    Ge W; Cao DD; Wang HM; Jie FF; Zheng YF; Chen Y
    Asian Pac J Cancer Prev; 2011; 12(11):2901-7. PubMed ID: 22393961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.
    Liu X; Guo Z; Su L; Zuo A; Gao M; Ji X; Lu J; Yang S; Jiang Y; Lu D
    Invest New Drugs; 2024 Jun; 42(3):309-317. PubMed ID: 38700579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of endostar® combined with chemotherapy in patients with advanced soft tissue sarcomas.
    Zhang LP; Liao XY; Xu YM; Yan LJ; Yan GF; Wang XX; Duan YZ; Sun JG
    Asian Pac J Cancer Prev; 2013; 14(7):4255-9. PubMed ID: 23991986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer.
    Zhou ZT; Zhou FX; Wei Q; Zou LY; Qin BF; Peng XS
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1027-32. PubMed ID: 21327933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis.
    An J; Lv W
    Thorac Cancer; 2018 May; 9(5):606-612. PubMed ID: 29575575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer.
    Bao Y; Peng F; Zhou QC; Yu ZH; Li JC; Cheng ZB; Chen L; Hu X; Chen YY; Wang J; Wang Y; Ma HL; Xu ZM; Lu RB; Deng XW; Chen M
    Radiother Oncol; 2015 Feb; 114(2):161-6. PubMed ID: 25497558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration.
    Xu H; Lv D; Meng Y; Wang M; Wang W; Zhou C; Zhou S; Chen X; Yang H
    Ann Palliat Med; 2020 Mar; 9(2):298-307. PubMed ID: 32075401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV.
    Xing P; Zhang J; Yan Z; Zhao G; Li X; Wang G; Yang Y; Zhao J; Xing R; Teng S; Ma Y; Liao Z; Ren Z; Zhang C; Han X; Zhang W; Chen K; Wang P; Yang J
    Oncotarget; 2017 May; 8(22):36716-36727. PubMed ID: 27888623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.